ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
ISSN 2383-9457 (ONLINE)
Adverse events data
| EMPA-REG OUTCOME6) | EMEPEROR-Reduced7) | EMEPEROR-Preserved8) | EMPULSE34) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Empagliflozin | Placebo | Empagliflozin 10 mg | Placebo | Empagliflozin 10 mg | Placebo | Empagliflozin 10 mg | Placebo | ||
| 10 mg | 25 mg | ||||||||
| Any serious adverse event | 37.4% | 39% | 42.3% | 41.4% | 48.1% | 47.9% | 51.6% | 32.3% | 43.6% |
| Volume depletion | 4.9% | 5.3% | 4.9% | 10.6% | 9.9% | - | - | - | - |
| Acute renal failure | 5.2% | 5.3% | 6.6% | - | - | 12.1% | 12.8% | 7.7% | 12.1% |
| Hypoglycemia | 28% | 27.6% | 27.9% | 1.4% | 1.5% | 2.4% | 2.6% | - | - |
| Hypotension | - | - | - | 9.4% | 8.7% | 10.4% | 8.6% | - | - |
| Ketoacidosis | 0.1% | <0.1% | <0.1% | 0% | 0% | 0.1% | 0.2% | 0% | 0% |
| Urinary tract infections | 18.2% | 17.8% | 18.1% | 4.9% | 4.5% | 9.9% | 8.1% | 4.2% | 6.4% |
| Genital infections | 6.5% | 6.3% | 1.8% | 1.7% | 0.6% | 2.2% | 0.7% | - | - |